Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
A Historical Cohort Study to Investigation of Statins Safety in Covid-19 Hospitalized Patients Publisher



Nateghi S1 ; Gomari MM2 ; Hosamirudsari H3 ; Behnoush B4 ; Razmjoofard A5 ; Azimi G1 ; Ordookhani S1 ; Jafarpour A6, 7 ; Faraji N1
Authors

Source: Therapies Published:2022


Abstract

Background and objectives: A notable proportion of COVID-19 patients need statins for their co-existing conditions. Statins possess several anti-inflammatory properties. We have attempted to describe potential association of exposure to statins and severity of COVID symtpoms in a historical study in hospitalized COVID-19 patients. Methods: This single-center, historical cohort study was performed in Baharloo hospital as a referral hospital for COVID-19 patients in Tehran. Patients were divided into two groups; 163 statins users and 547 non-users. Mortality rate, intensive care unit (ICU) admission and length of hospitalization were compared between studied groups. In addition, during the investigation, pre-existing conditions were evaluated for groups. If a significant difference was observed between groups, the feature was considered in the adjustment of the odds ratio. Results: At the beginning, statistical analysis study showed that statins users had significantly (p < 0.0001) higher mortality rate, ICU admission and length of hospitalization. But after implementation of variables such as age, sex, diabetes, hypertension status, stroke, dyslipidemia, cardiovascular diseases, chronic kidney disease (CKD), corticosteroids, renin-angiotensin-aldosterone axis inhibitors and proton pump inhibitors (PPIs) for adjustment of the odds ratio, a considerable alteration appeared in the studied values. Following adjustment of odds ratio it was shown that statins did not change mortality (95% CI, OR 0.71 (0.41–1.22), p = 0.22), ICU admission (95% CI, OR 1.05 (0.66–1.66), p = 0.835) and length of hospitalization (95% CI, OR 1.30 (0.78–2.17), p = 0.311). In addition, we found that statins could not decrease inflammatory markers in COVID-19 infected patients. Conclusion: The use of statins did not seem to change outcomes in COVID19. © 2021 Societe francaise de pharmacologie et de therapeutique
Other Related Docs
7. Effects of Statins on Renin–Angiotensin System, Journal of Cardiovascular Development and Disease (2021)
11. Analyzing Trends in Demographic, Laboratory, Imaging, and Clinical Outcomes of Icu-Hospitalized Covid-19 Patients, Canadian Journal of Infectious Diseases and Medical Microbiology (2023)
20. Covid-19’S Immuno-Pathology and Cardiovascular Diseases, Journal of Investigative Medicine (2023)